Praxis Precision Medicines Gains Momentum with Breakthrough Therapy Designation

Praxis Precision Medicines shares are trading higher after the FDA granted Breakthrough Therapy Designation for ulixacaltamide in treating essential tremor, based on promising Phase 3 results.